← All organizations

Stemline Therapeutics, Inc.

For profitContributed to NMEWebsite ↗

Also known as: STEMLINE THERAP | STEMLINE THERAPEEUTICS INC | Stemline Therapeutics, Inc. | STEMLINE THERAPEUTICS INC

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 2

First clinical trial

First marketed drug

First NDA

Last known activity

Dec 21, 2018

Acquired by Menarini Group on May 4, 2020

Timeline

2000s

Jul 1, 2003
Stemline Therapeutics, Inc.— Founded

2010s

Dec 21, 2018
tagraxofusp-erzs— Marketing Organization
Dec 21, 2018
tagraxofusp-erzs— NDA Organization

2020s

May 4, 2020
Menarini Group— Acquired By

Drugs by trial phase (10 distinct, 7 trials)

Phase 2 (8 own, 0 via acquisition)

Phase 1 (2 own, 0 via acquisition)

Indications

Studied for

Marketed drugs (2)

Recent trials (7)

NCT03113643CollaboratorPhase 1Jun 26, 2017
NCT02667873Lead sponsorPhase 1Feb 1, 2016
NCT02661022Lead sponsorPhase 1/Phase 2Jan 1, 2016
NCT02270463Lead sponsorPhase 1/Phase 2Feb 1, 2015
NCT02268253Lead sponsorPhase 1/Phase 2Dec 1, 2014
NCT02113982Lead sponsorPhase 1/Phase 2Sep 1, 2014
NCT02078648Lead sponsorPhase 1/Phase 2May 1, 2014

Details

Founded: New York, NY, US Jul 1, 2003
First NDA: Dec 21, 2018
Last known activity: Dec 21, 2018

Designations held

Orphan drug
Priority review
Breakthrough therapy